Travere Therapeutics (TVTX) EBT Margin (2014 - 2026)
Travere Therapeutics posted quarterly EBT Margin of 28.87% for Q1 2026, up 2152.0% year-on-year from 1.28% in Q1 2025, and down 582.06% on a QoQ basis from 5.99% in Q4 2025.
Travere Therapeutics (TVTX) has 13 years of EBT Margin data on file, last reported at 28.87% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin rose 2152.0% year-over-year to 28.87%; the trailing twelve-month figure through Mar 2026 stood at 63.93% (up 14653.0% YoY), and the FY2025 full-year result was 529.82%, down 39236.0% from the prior year.
- EBT Margin for Q1 2026 stood at 28.87%, down from 5.99% in the prior quarter.
- Across five years, EBT Margin topped out at 64.28% in Q3 2025 and bottomed at 348.94% in Q1 2022.
- The 5-year median for EBT Margin is 196.47% (2023), against an average of 172.31%.
- The widest annual swing landed in 2022, when EBT Margin tumbled 34777 bps; it then soared 27775 bps in 2025.
- A 5-year view of EBT Margin shows it stood at 291.67% in 2022, then soared by 33 bps to 196.47% in 2023, then jumped by 59 bps to 80.68% in 2024, then soared by 107 bps to 5.99% in 2025, then slumped by 582 bps to 28.87% in 2026.
- The last three EBT Margin figures came in at 28.87% (Q1 2026), 5.99% (Q4 2025), and 64.28% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.40% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 41.95% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 23.05% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 18.99% |
| 10 | Travere Therapeutics | 4.34 Bn | 4.26 Bn | 102.38 Mn | -28.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.87% |
| Dec 31, 2025 | 5.99% |
| Sep 30, 2025 | 64.29% |
| Jun 30, 2025 | -11.13% |
| Mar 31, 2025 | -50.39% |
| Dec 31, 2024 | -80.68% |
| Sep 30, 2024 | -87.18% |
| Jun 30, 2024 | -128.55% |
| Mar 31, 2024 | -328.15% |
| Dec 31, 2023 | -196.47% |
| Sep 30, 2023 | -240.54% |
| Jun 30, 2023 | -316.40% |
| Mar 31, 2023 | -312.37% |
| Dec 31, 2022 | -291.67% |
| Sep 30, 2022 | -298.91% |
| Jun 30, 2022 | -279.28% |
| Mar 31, 2022 | -348.94% |
| Dec 31, 2021 | 56.10% |
| Sep 30, 2021 | -64.72% |
| Jun 30, 2021 | -71.34% |
| Mar 31, 2021 | -112.97% |
| Dec 31, 2020 | -239.48% |
| Sep 30, 2020 | -44.05% |
| Jun 30, 2020 | -53.69% |
| Mar 31, 2020 | -38.03% |
| Dec 31, 2019 | -64.74% |
| Sep 30, 2019 | -83.41% |
| Jun 30, 2019 | -86.41% |
| Mar 31, 2019 | -102.54% |
| Dec 31, 2018 | -17.03% |
| Sep 30, 2018 | -132.91% |
| Jun 30, 2018 | -53.61% |
| Mar 31, 2018 | -47.22% |
| Dec 31, 2017 | -26.17% |
| Sep 30, 2017 | -47.14% |
| Jun 30, 2017 | -39.06% |
| Mar 31, 2017 | -39.13% |
| Dec 31, 2016 | -32.92% |
| Sep 30, 2016 | -90.28% |
| Jun 30, 2016 | -62.43% |
| Mar 31, 2016 | 21.19% |
| Dec 31, 2015 | -42.68% |
| Sep 30, 2015 | 515.40% |
| Jun 30, 2015 | -106.00% |
| Mar 31, 2015 | -2.11% |
| Dec 31, 2014 | -206.08% |
| Sep 30, 2014 | -215.38% |
| Jun 30, 2014 | 161.62% |
| Mar 31, 2014 | -270,253.57% |